DNA topoisomerase II in therapy-related acute promyelocytic leukemia. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D (2005) N Engl J Med 352: 1529-38 Anthracyclines and heart failure. Sawyer DB (2013) N Engl J Med 368: 1154-6 Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. Zechiedrich EL, Osheroff N (1990) EMBO J 9: 4555-62 Novobiocin inhibits passive chromatin assembly in vitro. Sealy L, Cotten M, Chalkley R (1986) EMBO J 5: 3305-11 Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, Felix CA (2001) Proc Natl Acad Sci U S A 98: 9802-7 In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Berrios M, Osheroff N, Fisher PA (1985) Proc Natl Acad Sci U S A 82: 4142-6 DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Lee S, Jung SR, Heo K, Byl JA, Deweese JE, Osheroff N, Hohng S (2012) Proc Natl Acad Sci U S A 109: 2925-30 Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Ackerman P, Glover CV, Osheroff N (1985) Proc Natl Acad Sci U S A 82: 3164-8 DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin condensation during apoptotic execution. Durrieu F, Samejima K, Fortune JM, Kandels-Lewis S, Osheroff N, Earnshaw WC (2000) Curr Biol 10: 923-6 Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide. DeVore RF, Corbett AH, Osheroff N (1992) Cancer Res 52: 2156-61 The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA-topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts. Dexheimer TS, Kozekova A, Rizzo CJ, Stone MP, Pommier Y (2008) Nucleic Acids Res 36: 4128-36 Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N (2003) Nucleic Acids Res 31: 4373-84 Proteomic analysis of human metaphase chromosomes reveals topoisomerase II alpha as an Aurora B substrate. Morrison C, Henzing AJ, Jensen ON, Osheroff N, Dodson H, Kandels-Lewis SE, Adams RR, Earnshaw WC (2002) Nucleic Acids Res 30: 5318-27 The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Gentry AC, Juul S, Veigaard C, Knudsen BR, Osheroff N (2011) Nucleic Acids Res 39: 1014-22 Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage. Deweese JE, Burgin AB, Osheroff N (2008) Nucleic Acids Res 36: 4883-93 Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Sabourin M, Osheroff N (2000) Nucleic Acids Res 28: 1947-54 Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, Monneret C, Osheroff N, Giovannangeli C, Arimondo PB (2006) Nucleic Acids Res 34: 1900-11 Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal. Frøhlich RF, Veigaard C, Andersen FF, McClendon AK, Gentry AC, Andersen AH, Osheroff N, Stevnsner T, Knudsen BR (2007) Nucleic Acids Res 35: 6170-80 The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Deweese JE, Osheroff N (2009) Nucleic Acids Res 37: 738-48 Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II. Baldwin EL, Berger AC, Corbett AH, Osheroff N (2005) Nucleic Acids Res 33: 1021-30 Direct measurement of DNA bending by type IIA topoisomerases: implications for non-equilibrium topology simplification. Hardin AH, Sarkar SK, Seol Y, Liou GF, Osheroff N, Neuman KC (2011) Nucleic Acids Res 39: 5729-43 Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Osheroff N (1989) Pharmacol Ther 41: 223-41 Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carroll M, Liu M, Osheroff N, Cheung NK, Slater DJ, Ried T, Knutsen T, Blair IA, Felix CA (2003) Oncogene 22: 8448-59 MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site. Slater DJ, Hilgenfeld E, Rappaport EF, Shah N, Meek RG, Williams WR, Lovett BD, Osheroff N, Autar RS, Ried T, Felix CA (2002) Oncogene 21: 4706-14 Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK (2017) Oncotarget 8: 43733-43751 Unraveling the structure of the variola topoisomerase IB-DNA complex: a possible new twist on smallpox therapy. Osheroff N (2006) Mol Interv 6: 245-8 Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, Väyrynen A, Kärkkäinen P, Moskaluk C, El-Rifai W, Knuutila S (2004) Int J Cancer 109: 548-53 Biological characterization of MLN944: a potent DNA binding agent. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA (2004) Mol Cancer Ther 3: 47-58 Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. Aldred KJ, Schwanz HA, Li G, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N (2013) ACS Chem Biol 8: 2660-8 Catalytic function of DNA topoisomerase II. Osheroff N, Zechiedrich EL, Gale KC (1991) Bioessays 13: 269-73 Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M, Osheroff N, Ahn NG (1999) Mol Cell Biol 19: 3551-60 Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. Abasic lesions as a tool to dissect enzyme mechanism. Kingma PS, Osheroff N (1998) J Biol Chem 273: 17999-8002 A two-drug model for etoposide action against human topoisomerase IIalpha. Bromberg KD, Burgin AB, Osheroff N (2003) J Biol Chem 278: 7406-12 Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism. Bromberg KD, Hendricks C, Burgin AB, Osheroff N (2002) J Biol Chem 277: 31201-6 Positioning the 3'-DNA terminus for topoisomerase II-mediated religation. Wilstermann AM, Osheroff N (2001) J Biol Chem 276: 17727-31 Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. Kingma PS, Osheroff N (1997) J Biol Chem 272: 7488-93 Base excision repair intermediates as topoisomerase II poisons. Wilstermann AM, Osheroff N (2001) J Biol Chem 276: 46290-6
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.